epocrates logo
epocrates logo
epocrates logo
  • Home
  • Search
  • Tools
  • Saved
  • 0
    Notifications
  • CME
  • Help & Feedback
  • About Us
  • Business Solutions

The clinical information you need, at your fingertips.

Medical News for You

Journal Article Synopsis

JAMA Psychiatry

1d

Ketamine eases treatment-resistant bipolar depression

In the first randomized trial of serial ketamine for bipolar depression, it roughly tripled response rates over midazolam. . .
Internally Generated Content

NIH

1d

Zebra of the Week: Warm autoimmune hemolytic anemia

A rare autoimmune cause of hemolytic anemia that can present with fatigue, jaundice, dark urine, and, in severe cases, cardiopulmonary compromise. . .
Journal Article Synopsis

AAFP

1d

AAFP updates COVID-19, RSV & flu vaccine guidance for 2026–27

Recommendations coordinated with AAP and other specialty organizations clarify vaccination across age and risk groups. . .
Government Health Agency News

FDA

1d

FDA adds boxed warning to ferric carboxymaltose for serious hypophosphatemia

New labeling emphasizes phosphate checks before repeat treatment and closer monitoring of at-risk patients. . .

Journal Article Synopsis

Eur Heart J

1d

ESC Congress 2026: Earlier treatment, simpler classification—new ESC guideline updates heart failure care

New classifications and expanded use of foundational therapies aim to simplify care and promote earlier treatment across the heart failure spectrum. . .
Journal Article Synopsis

Nat Microbiol

1d

Cancer drug reduces viral reservoir, advancing HIV cure research

Adding venetoclax when ART began produced a lasting response. . .
Journal Article Synopsis

Lancet Infect Dis

1d

Paxlovid again fails to ease long COVID

Even at 25 days, five times the standard course, nirmatrelvir-ritonavir moved no symptom measure in the largest randomized trial of antivirals for long COVID to date. . .

Journal Article Synopsis

JAMA Netw Open

1d

Saturated fat linked to higher mortality after prostate cancer

Cardiovascular disease and other cancers drove the excess deaths, while no fat measured was associated with prostate cancer mortality. . .
Journal Article Synopsis

Ann Intern Med

2d

Multi-pathway obesity drugs top weight loss charts

Investigational agents targeting GLP-1 plus amylin, GIP, or glucagon posted placebo-subtracted weight loss above 20%, while the approved menu grew to five drugs including two orals. . .

Trending icon

TRENDING THIS WEEK

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

About Us

Features

Business Solutions

Help & Feedback

Terms of Use

Privacy Policy

visit epocrates on instagram
visit epocrates on facebook
visit epocrates on youtube
visit epocrates on twitter
visit epocrates on linkedIn

© 2026 epocrates, Inc.

download epocrates on app storedownload epocrates on google play

Do not sell or share my personal information

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information